Skip to main content

FDA Approvals

FDA Approvals
Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer
Read More
FDA Approvals
Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure
Loretta Fala
Read More
FDA Approvals
Nivolumab Beats Docetaxel as Second-Line Therapy for Patients with NSCLC
Phoebe Starr
Read More
FDA Approvals
Oncology Pipeline Full, and Not Just with Immunotherapies
Caroline Helwick, Wayne Kuznar
Read More
FDA Approvals
FDA Update
Read More
FDA Approvals
CAR-T Cells: The Transplants of the Future
Chase Doyle
Read More
FDA Approvals
Encouraging Results for Pembrolizumab in Head and Neck Cancer
Phoebe Starr
Read More
FDA Approvals
Elotuzumab, First-in-Class Monoclonal Antibody Immuno­­therapy, Improves Outcomes in Patients with Multiple Myeloma
Phoebe Starr
Read More
FDA Approvals
Lenvatinib Extends Survival in Metastatic Renal-Cell Carcinoma
Wayne Kuznar
Read More
FDA Approvals
Nivolumab Makes Headwinds into Liver Cancer
Wayne Kuznar
Read More
Page 40 of 53
Results 391 - 400 of 525